AFT posts loss that meets estimates in maiden result as Australian sales overtake NZ

Pattrick Smellie
Tue, 24 May 2016

By Pattrick Smellie May 25 (BusinessDesk) - AFT Pharmaceuticals, the Auckland-based drug developer, posted a $8.9 million operating loss for the year to March 31, its first result since listing on the NZX and ASX last December, and in line with analyst expectations. Total revenue rose 14 percent to $64 million, in part reflecting ongoing fast sales growth in the Australian market of its flagship ibuprofen-paracetamol painkiller, Maxigesic. Australian sales rose 19 percent to $31.2 million while New Zealand revenue rose 5.8 percent to $31....

Not convinced yet?

Subscribe to our Daily News Update free newsletter.

Bloomberg
Warren Buffett’s Berkshire Hathaway ‘buys the dip’ again
Bloomberg | Mon, 08 Aug 2022

 The “Sage of Omaha” has emerged as a net buyer of equities in the June quarter, when markets were heading south around the world.

Bloomberg
What’s in the landmark US climate and tax bill
Bloomberg | Mon, 08 Aug 2022

After an epic struggle, the US Senate has passed a landmark climate change, tax and healthcare bill that Joe Biden hopes will help the Democrats in the mid-term elections.

Property
Wellington house price decline 'worst in world'
Brent Melville | Mon, 08 Aug 2022

Wellington is taking the brunt of the New Zealand housing market's sharp decline, dragged down by rising mortgage rates and tough credit conditions.

Sponsored
Energy of the future: Why we need innovation

The Tomorrow’s Energy Today conference is looking at ways to develop a clean, affordable and reliable energy future, says Brendan Winitana, chair of the Sustainable Energy Association New Zealand (SEANZ).

Sponsored
David Kelly: 'We must learn from past mistakes'

The CEO of the Registered Master Builders Association calls for the government and the building sector to create more resilience.